Question 1

Who are the top researchers at Genoscience Pharma (France)?

Accepted Answer

Ranked on the quality score, Eloïne Bestion, Madani Rachid and V. V. Chmil lead among researchers whose main affiliation is Genoscience Pharma (France).

Question 2

What are the most cited papers from Genoscience Pharma (France)?

Accepted Answer

The most cited paper from Genoscience Pharma (France) is "Monocytes and Macrophages, Targets of Severe Acute Respiratory Syndrome Coronavirus 2: The Clue for Coronavirus Disease 2019 Immunoparalysis" (Asma Fatima Boumaza, Laëtitia Gay, Soraya Mezouar et al., 2021), with 183 citations. Next come "Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221" (93) and "GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions" (91).

Question 3

Which research topics does Genoscience Pharma (France) publish most on?

Accepted Answer

By volume in 2022-now: Malaria Research and Control, Vector-borne infectious diseases, Asian Studies and History and Zoonotic diseases and public health.

Question 4

Which keywords describe research at Genoscience Pharma (France)?

Accepted Answer

By fractional works in 2022-now, weighted toward what it does more of than the world: Epidemiology, Pathogen Transmission, Vaccine Development, Public Health, Global Burden, Artemisinin Resistance, Plasmodium falciparum and Lyme Disease.

Question 5

Which fields of science does Genoscience Pharma (France) work in?

Accepted Answer

In 2022-now, 40% of research at Genoscience Pharma (France) is in Life Sciences, 38% in Health Sciences. Its largest fields are Medicine (35%), Immunology and Microbiology (17%), Biochemistry, Genetics and Molecular Biology (17%). It does 2.0× the world's share of Life Sciences.

Question 6

Is Genoscience Pharma (France)'s research output growing?

Accepted Answer

Output in 2022-2025 was 235% higher than in 2018-2021.